Like the police boot that keeps your car off the road, certain antibodies can stop pathological tau in its tracks and prevent it from infiltrating neurons, according to a paper in today’s Neuron online. Scientists led by joint senior authors David Holtzman and Marc Diamond at Washington University in St. Louis, Missouri, screened a panel of tau antibodies and identified those that appear to specifically interfere with tau’s extracellular spread from neuron to neuron. A slow, steady infusion of these antibodies into mouse brains reduced tau pathology and offered a hint at cognitive improvement in a test measuring the animals’ recollection of past electric shocks. Not only does the work suggest a potential treatment for tauopathies, it also provides support for a burgeoning hypothesis that extracellular tau travels from cell to cell much like a prion. “This suggests that yes, extracellular tau is very likely to be playing a role in pathology,” Diamond said.
“This work is fantastic,” commented Eckhard Mandelkow of the German Center for Neurodegenerative Diseases in Bonn, in an email to Alzforum (see full comment below). “It explains why antibody therapy might work for tau pathology…antibodies only have to reach extracellular tau.”
Antibodies against extracelluar, aggregated tau markedly reduce tau pathology in cortex of P301S tau-transgenic mice.Courtesy of David Holtzman, Marc Diamond and Kiran Yanamandra, Washington University, St. Louis, Missouri
Diamond’s group, and others, are pursuing the hypothesis that when neurons spit out toxic tau, it travels to and invades adjacent cells, corrupting their healthy tau into more of the pathological species (see ARF news story and ARF news story, Clavaguera et al., 2009 ). This theory would explain the established and stereotypical progression of tau through the brain of people with Alzheimer’s, starting in the locus coeruleus and moving into the transentorhinal cortex, then hippocampus, then further (Braak and Del Tredici, 2011). Therefore, scientists reason, an antibody or other blocking agent that captures and detains extracellular tau should halt this spread. While several research groups have attempted to vaccinate animals against tau, with varying success rates, no one before has specifically taken aim at the transitory tau species in the exact way Diamond and Holtzman did in this study (see ARF news story, ARF news story; Bi et al., 2011, Boimel et al., 2010, Troquier 2012, Boutajangout et al., 2011. Chai et al., 2011, Rosenmann et al., 2006). ”The effect of [our] antibodies is very strong in comparison to what has been published,” Holtzman told Alzforum.
When Holtzman’s lab first became interested in tau, the group generated a series of antibodies as tools for experiments such as immunohistochemistry and immunoprecipitation. The Diamond lab, meanwhile, developed a cell culture assay to study the uptake of extracellular tau and seeding of new intracellular fibrils (Kfoury et al., 2012). The two crews joined forces for the current study, helmed by first author Kiran Yanamandra, to identify antibodies that could obstruct tau seeding.
In Diamond’s seeding-sensing assay, human embryonic kidney (HEK293) cells express tau fragments fused to either yellow or cyan fluorescent protein. If seeding occurs, the two colors meet in newly created, intracellular tau aggregates and produce a signal by fluorescence resonance energy transfer (FRET). The researchers exposed the cells to brain lysates from mice expressing human tau with a proline-301-serine mutation (see Alzforum Research Models and ARF news story. Normally, the aggregated tau in these lysates invades the HEK293 cells, recruits their endogenous tau, and produces FRET.
Holtzman’s antibodies impeded tau seeding to varying degrees in the sensor assay. Diamond suspects they work by preventing the kidney cells from taking up extracellular tau. For their in-vivo experiments, the researchers selected three antibodies with high, medium, and low activity in preventing seeding. HJ8.5, a mouse monoclonal raised against human tau, put the strongest block on seeding. HJ9.3, which was raised against mouse tau but also recognizes the human protein, was the medium-efficacy representative. HJ9.4, also raised against mouse tau with low affinity for human tau, was the weakest. As negative controls, the researchers used phosphate-buffered saline or the antibody HJ3.4, which ignores tau but binds Aβ instead.
Block Seeding, Block Disease?
In the Washington University mouse colony, P301S mice first develop tau pathology around five months of age, so the researchers began their treatment at six months. They implanted tiny catheters into the left lateral ventricles of the animals and slowly, continuously infused the antibodies. After three months, they sacrificed the animals and examined their brains. The highest-activity antibody HJ8.5 strongly diminished staining with the phospho-tau antibody AT8, while the other two antibodies causes a smaller reduction. HJ8.5 also reduced staining with the amyloid marker thioflavin S, which labels both amyloid plaques and neurofibrillary tangles.
In addition, the high-activity HJ8.5 and medium-activity HJ9.3 also reduced microgliosis, which HJ9.4 did to a lesser extent. And in biochemical assays, Yanamandra and colleagues observed that the high- and medium-efficacy antibodies HJ8.5 and HJ9.3 diminished the fraction of total tau that was detergent insoluble, indicating the antibodies had interfered with aggregation.
Next, the researchers returned to the FRET sensor assay with brain lysates from the antibody-treated mice. HJ8.5 and HJ9.3 treatment reduced the seeding efficacy of these lysates, while low-efficacy antibody HJ9.4 did not. This supports the original theory that the antibodies would protect neurons by blocking seeding, Holtzman said.
Less Tau, Better Memory?
Would the antibody treatment affect mouse behavior? The researchers tried several tests, Holtzman said, and found these P301S mice to be abnormal in their conditioned fear response. In this test, 8.5-month-old animals spend time in a chamber where they learn to associate a sound with an electric shock. The following day, the researchers return the animals to the same chamber and track how much time they spend moving around versus frozen with fear. Mice that have formed unpleasant memories of the chamber spend less time in motion. This association is known to require hippocampal function.
On that second day, freeze time in the control P301S mice was 5-10 percent, averaged over an eight-minute session. With the antibody-treated animals, the results did not entirely parallel the pathological data. HJ8.5 treatment resulted in nearly 30 percent freeze time, HJ9.3 treatment in 10 percent, and HJ9.4 treatment in about 20 percent freezing.
Because the antibodies’ ability to block seeding did not line up neatly with their behavioral effects, it is unclear that they affect contextual fear by interfering with seeding, noted Karen Ashe of the University of Minnesota in Minneapolis, who was not involved with the study. Holtzman agreed that the researchers cannot be certain of the precise mechanism for the behavioral results beyond saying that they are an effect on some form of tau.
Ashe, as well as Miranda Reed of West Virginia University in Morgantown, questioned the behavior part of the study because it included no wild-type control in the same experiments as the treated mice. Further, Jackson Laboratories, the source of the mice, has reported that the animals have limb weakness that leads to paralysis (see JAX Mice Database). “Without the [wild-type] controls, it is hard to interpret the data,” Ashe told Alzforum. “I am wary of interpreting cognitive data that depends upon a physical readout in an animal that may be physically impaired.”
Holtzman said that the P301S colony at Washington University does not have the reported motor defects, aside from occasional walking difficulties in animals older than one year. It is common for mouse models of degenerative diseases to show differing phenotypes, depending on the outcrosses used to maintain the lines and other variables in the colony, Diamond noted. Wild-type mice typically spend 30-50 percent of their time frozen on their second day in the chamber, Holtzman told Alzforum.
Regardless of the details of the behavioral assays, the study authors say their results support the hypothesis that tau transmission relies on an extracellular, prion-like mechanism, and others agreed. “This suggests that antibody-based therapies may be able to stop the progressive spread of tau tangles in the brain of those affected by Alzheimer’s disease,” wrote Amy Pooler of King’s College London, U.K., in an email to Alzforum (see full comment below). “However, more work will need to be done to determine the mechanism by which the tau/antibody complexes are cleared from the brain.” The researchers are not sure what happens to antibody-bound tau, but they noticed much of it disappeared from the brain and entered the bloodstream. Presumably, immune cells would then eliminate the complexes. Microglia might do the same inside the central nervous system, but this is unproven.
Tau Transit Treatments?
From these data, Diamond concluded that blocking the prion-like transmission of tau would be a good way to design therapeutic antibodies. He and Holtzman said they want to pursue an anti-tau transit therapy. Referring to confidentiality agreements, the authors declined to take questions about how their antibodies might be developed further. The Neuron paper acknowledges funding by the Tau Consortium, a philanthropy started by Texas billionaire Richard Rainwater, and the company C2N Diagnostics, which Holtzman co-founded. Clinical development will first require more mouse experiments to determine if the antibody works when delivered peripherally, instead of directly to the brain. Peripheral delivery would be much more practical for human therapy.
As a first disease target, it makes sense to try a pure tauopathy such as progressive supranuclear palsy, corticobasal degeneration, or tau-based frontotemporal dementia, Holtzman suggested. Alzheimer’s disease is complicated by the co-occurrence of amyloid-beta pathology.
“It is nice to see that people are continuing to get positive effects with tau immunotherapy,” commented Einar Sigurdsson of New York University, who was not involved in this work but has been studying tau immunotherapy since the beginning of that field. Pharmaceutical companies might be attracted to antibodies against extracellular tau, Sigurdsson added, because they do not have to worry about getting the antibodies inside neurons. Such anti-tau therapies would be analogous to anti-amyloid-beta immunotherapy against extracellular plaques (see Alzforum News story on DeMattos et al., 2001; and Bard et al., 2000). Passive immunotherapy is ideal for proof-of-concept studies, but could be less practical for widespread patient use, Sigurdsson believes, because the antibodies are expensive and require regular dosing. Eventually, researchers might be able to come up with active tau immunization protocols that induce lasting immunity with fewer treatment sessions.—Amber Dance
- Double Paper Alert—Keystone Presentations Now in Press
- Tau Vaccine Detangles Mouse Brain
- San Diego: Tau Oligomer Antibodies Relieve Motor Deficits in Mice
- Tau Toxicity—Tangle-free But Tied to Inflammation
- Two Ways to Attack Amyloid: Metal Chelator and Antibody
- Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009 Jul;11(7):909-13. PubMed.
- Braak H, Del Tredici K. Alzheimer's pathogenesis: is there neuron-to-neuron propagation?. Acta Neuropathol. 2011 May;121(5):589-95. PubMed.
- Bi M, Ittner A, Ke YD, Götz J, Ittner LM. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One. 2011;6(12):e26860. PubMed.
- Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol. 2010 Aug;224(2):472-85. PubMed.
- Troquier L, Caillierez M, Burnouf S, Fernandez-Gomez FJ, Grosjean MJ, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L. Targeting phospho-Ser422 by active Tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012 Jan 23; PubMed.
- Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011 Aug;118(4):658-67. PubMed.
- Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem. 2011 Sep 30;286(39):34457-67. PubMed.
- Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol. 2006 Oct;63(10):1459-67. PubMed.
- Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular Propagation of Tau Aggregation by Fibrillar Species. J Biol Chem. 2012 Jun 1;287(23):19440-51. PubMed.
- DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850-5. Epub 2001 Jul 3 PubMed.
- Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000 Aug;6(8):916-9. PubMed.
- Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010 Mar;11(3):155-9. PubMed.
- Gu J, Sigurdsson EM. Immunotherapy for tauopathies. J Mol Neurosci. 2011 Nov;45(3):690-5. PubMed.
- Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res. 2009 Oct;6(5):446-50. PubMed.
- Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis. 2008 Oct;15(2):157-68. PubMed.
- Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013 Sep 5;501(7465):45-51. PubMed.
- Double Paper Alert—Keystone Presentations Now in Press
- Are Protein Strains The Cause of Different Tauopathies?
- An Extra Strain on the Brain—α-Synuclein Seeds Tau Aggregation
- Tau, α-Synuclein Spread: Crazy Stuff—How Might It Work?
- In Case You Wondered: Neurodegenerative Diseases Are Not Contagious
- Chicago—ALS Protein SOD1 Painted as Disease Template
- Aβ Sufficient for Seeding—But Is It a Prion?
- Proteopathic Seeds and Neurodegenerative Diseases
- Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo. Neuron. 2013 Oct 16;80(2):402-14. PubMed.